# A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets

> **NCT07170800** · PHASE2 · RECRUITING · sponsor: **WestVac Biopharma Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Tuberculosis
- Multidrug Resistant Pulmonary Tuberculosis
- Rifampicin-resistant Tuberculosis

## Interventions

- **DRUG:** JDB0131 100mg
- **DRUG:** JDB0131 200mg
- **DRUG:** Delamanid (D)

## Key facts

- **NCT ID:** NCT07170800
- **Lead sponsor:** WestVac Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-19
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-09-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07170800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07170800, "A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT07170800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*